Mecamylamine reduces some EEG effects of nicotine chewing gum in humans.
Spontaneous EEG was recorded in nine cigarette smokers who had been abstinent from tobacco for 12 hr. Subjects were treated with a capsule containing either centrally acting nicotine blocker, mecamylamine (10 mg), or placebo. At each of three 60-min intervals after the capsule was ingested, the subjects chewed two pieces of gum containing a total of 0, 4 or 8 mg of nicotine. Nicotine and mecamylamine dose combinations were randomized across subjects. Two three-minute periods of spontaneous EEG were recorded before the capsule and before and after gum chewing from bipolar electrode montages at the following positions: Cz-T5, Cz-T6, Cz-F7 and Cz-F8. During one period the subjects relaxed with eyes closed, in the other period they performed a math task with eyes open. When the drugs were given individually, mecamylamine decreased beta power and nicotine gum (4 and 8 mg) increased alpha frequency. Mecamylamine pretreatment prevented the increase in alpha frequency caused by the 4 mg gum dose but not the 8 mg dose. Alpha power was increased by the 8 mg gum dose and that increase was prevented by mecamylamine. Self-reported ratings of the "strength" of the gum were significantly diminished by mecamylamine pretreatment. The data are consistent with the results of earlier studies which indicate that the effects of tobacco administration and withdrawal are mediated by central actions of nicotine.
Pickworth
W B
WB
NIDA Addiction Research Center, Baltimore, MD 21224.
Herning
R I
RI
Henningfield
J E
JE
D000328:Adult; D002638:Chewing Gum; D004569:Electroencephalography; D006801:Humans; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology*; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014029:Tobacco Use Disorder / Q000503:physiopathology
D002638:Chewing Gum; D008464:Mecamylamine; D009538:Nicotine